Next Article in Journal
Biological and Pathological Studies of Rosmarinic Acid as an Inhibitor of Hemorrhagic Trimeresurus flavoviridis (habu) Venom
Next Article in Special Issue
Toxin-Based Therapeutic Approaches
Previous Article in Journal
Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of Cancer
Previous Article in Special Issue
Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy
Article Menu

Export Article

Open AccessReview
Toxins 2010, 2(10), 2467-2477; doi:10.3390/toxins2102467

Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy

1
Department of Medical Biosciences, Umeå University, S-901 85 Umea, Sweden
2
Department of Odontology, Umeå University, S-901 85 Umea, Sweden
*
Author to whom correspondence should be addressed.
Received: 19 September 2010 / Revised: 15 October 2010 / Accepted: 19 October 2010 / Published: 25 October 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [229 KB, uploaded 25 October 2010]   |  

Abstract

A major problem with anti-cancer drug treatment is the development of acquired multidrug resistance (MDR) of the tumor cells. Verotoxin-1 (VT-1) exerts its cytotoxicity by targeting the globotriaosylceramide membrane receptor (Gb3), a glycolipid associated with multidrug resistance. Gb3 is overexpressed in many human tumors and tumor cell lines with inherent or acquired MDR. Gb3 is co-expressed and interplays with the membrane efflux transporter P-gp encoded by the MDR1 gene. P-gp could act as a lipid flippase and stimulate Gb3 induction when tumor cells are exposed to cancer chemotherapy. Recent work has shown that apoptosis and inherent or acquired multidrug resistance in Gb3-expressing tumors could be affected by VT-1 holotoxin, a sub-toxic concentration of the holotoxin concomitant with chemotherapy or its Gb3-binding B-subunit coupled to cytotoxic or immunomodulatory drug, as well as chemical manipulation of Gb3 expression. The interplay between Gb3 and P-gp thus gives a possible physiological approach to augment the chemotherapeutic effect in multidrug resistant tumors. View Full-Text
Keywords: apoptosis; cancer; Gb3; verotoxin-1; multi-drug resistance; MDR1; P-gp apoptosis; cancer; Gb3; verotoxin-1; multi-drug resistance; MDR1; P-gp
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Behnam-Motlagh, P.; Tyler, A.; Grankvist, K.; Johansson, A. Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy. Toxins 2010, 2, 2467-2477.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top